News
Important Only
BRIEF-Northstrive Biosciences, Subsidiary of PMGC Holdings, Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
Feb 4 (Reuters) - PMGC Holdings Inc ELAB.O:PMGC UNIT, NORTHSTRIVE, SAYS PREPARING FOR FDA INVESTIGATIONAL NEW DRUG FILING FOR EL-22NORTHSTRIVE - ANTICIPATES TYPE B PRE-IND MEETING WITH FDA IN Q2 2025Source text: ID:nGNX8gZXxSFurther company coverage: ELAB.OReuters
Tue, Feb 4
CORRECTED-Trial of man in Salman Rushdie stabbing begins with jury selection
Corrects paragraph 8 to show trial is taking place in Mayville, not MayfieldHadi Matar has pleaded not guilty to second-degree attempted murder and assaultRushdie due to testify about 2022 attack Feb 4 (Reuters) - The trial of the man charged with attempting to murder the novelist Salman Rushdie ...Reuters
Tue, Feb 4
China announces measures against Google, other US firms, as trade tensions escalate
China takes action minutes after US tariffs come into effectRegulator probes Google for suspected breach of anti-monopoly lawPVH, Illumina placed on 'unreliable entity' listUS farm equipment makers slapped with 10% tariffChina's tariffs take effect on Feb 10Adds PVH's response in par...Reuters
Tue, Feb 4
BRIEF-Innoviz Announces Optimization of Operations to Accelerate Path to Profitability
Feb 4 (Reuters) - Innoviz Technologies Ltd INVZ.O:INNOVIZ TECHNOLOGIES LTD: REALIGNMENT ACTIONS TO BE IMPLEMENTED DURING FIRST HALF OF 2025INNOVIZ TECHNOLOGIES LTD: REALIGNMENT ACTIONS EXPECTED TO REDUCE CASH OUTLAYS BY ABOUT $12 MILLION ON AN ANNUALIZED BASISINNOVIZ TECHNOLOGIES LTD: PLANS TO DE...Reuters
Tue, Feb 4
BRIEF-Agnico Eagle and O3 Mining Announce Subsequent Acquisition Transaction and Completion of Offer
Feb 4 (Reuters) - Agnico Eagle Mines Ltd AEM.TO:AGNICO EAGLE AND O3 MINING ANNOUNCE SUBSEQUENT ACQUISITION TRANSACTION AND COMPLETION OF OFFERSource text: ID:nCNWn0T8baFurther company coverage: AEM.TOReuters
Tue, Feb 4
BRIEF-Semler Scientific® Announces Updated BTC Activity; Monetizes Minority Investment to Purchase BTC; Purchased Additional 871 BTC; Now Holds 3,192 BTC; YTD BTC Yield of 152.2% Since July 1, 2024
Feb 4 (Reuters) - Semler Scientific Inc SMLR.O:SEMLER SCIENTIFIC® ANNOUNCES UPDATED BTC ACTIVITY; MONETIZES MINORITY INVESTMENT TO PURCHASE BTC; PURCHASED ADDITIONAL 871 BTC; NOW HOLDS 3,192 BTC; YTD BTC YIELD OF 152.2% SINCE JULY 1, 2024Source text: ID:nPn8PrS9zaFurther company coverage: SMLR.OReuters
Tue, Feb 4
BRIEF-Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Feb 4 (Reuters) - Rezolute Inc RZLT.O:REZOLUTE PROVIDES UPDATE ON ITS PHASE 3 SUNRIZE STUDY OF ERSODETUG FOR THE TREATMENT OF HYPOGLYCEMIA DUE TO CONGENITAL HYPERINSULINISMREZOLUTE INC - SUNRIZE ENROLLMENT COMPLETION EXPECTED IN Q2 2025REZOLUTE INC - DMC REVIEWED OPEN-LABEL ARM FOR INFANTS, TARGET D...Reuters
Tue, Feb 4
BRIEF-McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings, LLC
Feb 4 (Reuters) - Mckesson Corp MCK.N:MCKESSON ADVANCES SPECIALTY LEADERSHIP; SIGNS AGREEMENT TO ACQUIRE CONTROLLING INTEREST IN PRISM VISION HOLDINGS, LLCMCKESSON CORP - TO PURCHASE 80% INTEREST IN PRISM VISION FOR $850 MILLIONMCKESSON CORP - PRISM VISION EXPECTED TO BE $0.20-$0.30 ACCRETIVE TO MCK...Reuters
Tue, Feb 4
BRIEF-Vacasa Confirms Receipt of Unsolicited Non-Binding Acquisition Proposal from Davidson Kempner Capital Management
Feb 4 (Reuters) - Vacasa Inc VCSA.O:VACASA CONFIRMS RECEIPT OF UNSOLICITED NON-BINDING ACQUISITION PROPOSAL FROM DAVIDSON KEMPNER CAPITAL MANAGEMENTVACASA INC - RECEIVES UNSOLICITED PROPOSAL FROM DAVIDSON KEMPNER CAPITAL MANAGEMENT AT $5.25 PER SHAREVACASA INC - SPECIAL COMMITTEE TO REVIEW DAVIDSON ...Reuters
Tue, Feb 4
BRIEF-Zoetis Announces U.S. Label Update for Librela® (bedinvetmab injection), a Treatment to Control Canine Osteoarthritis (OA) Pain
Feb 4 (Reuters) - Zoetis Inc ZTS.N:ZOETIS ANNOUNCES U.S. LABEL UPDATE FOR LIBRELA® (BEDINVETMAB INJECTION), A TREATMENT TO CONTROL CANINE OSTEOARTHRITIS (OA) PAINZOETIS INC: PLANS TO IMMEDIATELY IMPLEMENT UPDATED LABEL BASED ON U.S. POST-APPROVAL EXPERIENCE WITH LIBRELAZOETIS INC: REMAINS CONFIDENT ...Reuters
Tue, Feb 4
U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
Feb 4 (Reuters) - The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' SUPN.O drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.Reuters
Tue, Feb 4
